Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
We conducted a pooled analysis of 869 individual newly diagnosed elderly patient data from 3 prospective trials. At diagnosis, a geriatric assessment had been performed. An additive scoring system (range 0-5), based on age, comorbidities, and cognitive and physical conditions, was developed to ident...
Uložené v:
| Vydané v: | Blood Ročník 125; číslo 13; s. 2068 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
26.03.2015
|
| Predmet: | |
| ISSN: | 1528-0020, 1528-0020 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | We conducted a pooled analysis of 869 individual newly diagnosed elderly patient data from 3 prospective trials. At diagnosis, a geriatric assessment had been performed. An additive scoring system (range 0-5), based on age, comorbidities, and cognitive and physical conditions, was developed to identify 3 groups: fit (score = 0, 39%), intermediate fitness (score = 1, 31%), and frail (score ≥2, 30%). The 3-year overall survival was 84% in fit, 76% in intermediate-fitness (hazard ratio [HR], 1.61; P = .042), and 57% in frail (HR, 3.57; P < .001) patients. The cumulative incidence of grade ≥3 nonhematologic adverse events at 12 months was 22.2% in fit, 26.4% in intermediate-fitness (HR, 1.23; P = .217), and 34.0% in frail (HR, 1.74; P < .001) patients. The cumulative incidence of treatment discontinuation at 12 months was 16.5% in fit, 20.8% in intermediate-fitness (HR, 1.41; P = .052), and 31.2% in frail (HR, 2.21; P < .001) patients. Our frailty score predicts mortality and the risk of toxicity in elderly myeloma patients. The International Myeloma Working group proposes this score for the measurement of frailty in designing future clinical trials. These trials are registered at www.clinicaltrials.gov as #NCT01093136 (EMN01), #NCT01190787 (26866138MMY2069), and #NCT01346787 (IST-CAR-506). |
|---|---|
| AbstractList | We conducted a pooled analysis of 869 individual newly diagnosed elderly patient data from 3 prospective trials. At diagnosis, a geriatric assessment had been performed. An additive scoring system (range 0-5), based on age, comorbidities, and cognitive and physical conditions, was developed to identify 3 groups: fit (score = 0, 39%), intermediate fitness (score = 1, 31%), and frail (score ≥2, 30%). The 3-year overall survival was 84% in fit, 76% in intermediate-fitness (hazard ratio [HR], 1.61; P = .042), and 57% in frail (HR, 3.57; P < .001) patients. The cumulative incidence of grade ≥3 nonhematologic adverse events at 12 months was 22.2% in fit, 26.4% in intermediate-fitness (HR, 1.23; P = .217), and 34.0% in frail (HR, 1.74; P < .001) patients. The cumulative incidence of treatment discontinuation at 12 months was 16.5% in fit, 20.8% in intermediate-fitness (HR, 1.41; P = .052), and 31.2% in frail (HR, 2.21; P < .001) patients. Our frailty score predicts mortality and the risk of toxicity in elderly myeloma patients. The International Myeloma Working group proposes this score for the measurement of frailty in designing future clinical trials. These trials are registered at www.clinicaltrials.gov as #NCT01093136 (EMN01), #NCT01190787 (26866138MMY2069), and #NCT01346787 (IST-CAR-506). We conducted a pooled analysis of 869 individual newly diagnosed elderly patient data from 3 prospective trials. At diagnosis, a geriatric assessment had been performed. An additive scoring system (range 0-5), based on age, comorbidities, and cognitive and physical conditions, was developed to identify 3 groups: fit (score = 0, 39%), intermediate fitness (score = 1, 31%), and frail (score ≥2, 30%). The 3-year overall survival was 84% in fit, 76% in intermediate-fitness (hazard ratio [HR], 1.61; P = .042), and 57% in frail (HR, 3.57; P < .001) patients. The cumulative incidence of grade ≥3 nonhematologic adverse events at 12 months was 22.2% in fit, 26.4% in intermediate-fitness (HR, 1.23; P = .217), and 34.0% in frail (HR, 1.74; P < .001) patients. The cumulative incidence of treatment discontinuation at 12 months was 16.5% in fit, 20.8% in intermediate-fitness (HR, 1.41; P = .052), and 31.2% in frail (HR, 2.21; P < .001) patients. Our frailty score predicts mortality and the risk of toxicity in elderly myeloma patients. The International Myeloma Working group proposes this score for the measurement of frailty in designing future clinical trials. These trials are registered at www.clinicaltrials.gov as #NCT01093136 (EMN01), #NCT01190787 (26866138MMY2069), and #NCT01346787 (IST-CAR-506).We conducted a pooled analysis of 869 individual newly diagnosed elderly patient data from 3 prospective trials. At diagnosis, a geriatric assessment had been performed. An additive scoring system (range 0-5), based on age, comorbidities, and cognitive and physical conditions, was developed to identify 3 groups: fit (score = 0, 39%), intermediate fitness (score = 1, 31%), and frail (score ≥2, 30%). The 3-year overall survival was 84% in fit, 76% in intermediate-fitness (hazard ratio [HR], 1.61; P = .042), and 57% in frail (HR, 3.57; P < .001) patients. The cumulative incidence of grade ≥3 nonhematologic adverse events at 12 months was 22.2% in fit, 26.4% in intermediate-fitness (HR, 1.23; P = .217), and 34.0% in frail (HR, 1.74; P < .001) patients. The cumulative incidence of treatment discontinuation at 12 months was 16.5% in fit, 20.8% in intermediate-fitness (HR, 1.41; P = .052), and 31.2% in frail (HR, 2.21; P < .001) patients. Our frailty score predicts mortality and the risk of toxicity in elderly myeloma patients. The International Myeloma Working group proposes this score for the measurement of frailty in designing future clinical trials. These trials are registered at www.clinicaltrials.gov as #NCT01093136 (EMN01), #NCT01190787 (26866138MMY2069), and #NCT01346787 (IST-CAR-506). |
| Author | Kumar, Shaji K Moreau, Philippe Musto, Pellegrino Terpos, Evangelos Zweegman, Sonja Mateos, Maria-Victoria Stewart, A Keith Offidani, Massimo Sonneveld, Pieter San Miguel, Jesus F Rajkumar, S Vincent Dimopoulos, Meletios A McCarthy, Philip Palumbo, Antonio Evangelista, Andrea Lonial, Sagar Ludwig, Heinz Anderson, Kenneth Richardson, Paul Landgren, Ola Bringhen, Sara Facon, Thierry Hajek, Roman Larocca, Alessandra Durie, Brian G M Belch, Andrew Einsele, Hermann |
| Author_xml | – sequence: 1 givenname: Antonio surname: Palumbo fullname: Palumbo, Antonio organization: Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy – sequence: 2 givenname: Sara surname: Bringhen fullname: Bringhen, Sara organization: Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy – sequence: 3 givenname: Maria-Victoria surname: Mateos fullname: Mateos, Maria-Victoria organization: Servicio de Hematología, Hospital Universitario de Salamanca, Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca-Centro Superior de Investigaciones Científicas, Salamanca, Spain – sequence: 4 givenname: Alessandra surname: Larocca fullname: Larocca, Alessandra organization: Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy – sequence: 5 givenname: Thierry surname: Facon fullname: Facon, Thierry organization: Department of Hematology, University Hospital, Lille, France – sequence: 6 givenname: Shaji K surname: Kumar fullname: Kumar, Shaji K organization: Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN – sequence: 7 givenname: Massimo surname: Offidani fullname: Offidani, Massimo organization: Clinica di Ematologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy – sequence: 8 givenname: Philip surname: McCarthy fullname: McCarthy, Philip organization: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY – sequence: 9 givenname: Andrea surname: Evangelista fullname: Evangelista, Andrea organization: Unit of Clinical Epidemiology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy – sequence: 10 givenname: Sagar surname: Lonial fullname: Lonial, Sagar organization: Department of Hematology and Medical Oncology, Emory University, Atlanta, GA – sequence: 11 givenname: Sonja surname: Zweegman fullname: Zweegman, Sonja organization: Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands – sequence: 12 givenname: Pellegrino surname: Musto fullname: Musto, Pellegrino organization: Scientific Direction, Istituto di Ricovero e Cura a Carattere Scientifico, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy – sequence: 13 givenname: Evangelos surname: Terpos fullname: Terpos, Evangelos organization: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece – sequence: 14 givenname: Andrew surname: Belch fullname: Belch, Andrew organization: Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada – sequence: 15 givenname: Roman surname: Hajek fullname: Hajek, Roman organization: Department of Haematooncology and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic – sequence: 16 givenname: Heinz surname: Ludwig fullname: Ludwig, Heinz organization: Department of Oncology, Hematology and Palliative Care, Wilhelminen, Vienna, Austria – sequence: 17 givenname: A Keith surname: Stewart fullname: Stewart, A Keith organization: Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ – sequence: 18 givenname: Philippe surname: Moreau fullname: Moreau, Philippe organization: Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France – sequence: 19 givenname: Kenneth surname: Anderson fullname: Anderson, Kenneth organization: Department of Hematology/Oncology, Dana-Farber Cancer Institute, Boston, MA – sequence: 20 givenname: Hermann surname: Einsele fullname: Einsele, Hermann organization: Medical Clinic and Polyclinic II, Department of Internal Medicine II, University Hospital, Wuerzburg, Germany – sequence: 21 givenname: Brian G M surname: Durie fullname: Durie, Brian G M organization: Department of Hematology/Oncology, Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA – sequence: 22 givenname: Meletios A surname: Dimopoulos fullname: Dimopoulos, Meletios A organization: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece – sequence: 23 givenname: Ola surname: Landgren fullname: Landgren, Ola organization: Multiple Myeloma section, National Cancer Institute, Bethesda, MD – sequence: 24 givenname: Jesus F surname: San Miguel fullname: San Miguel, Jesus F organization: Clínica Universidad de Navarra, Centro de Investigaciones Médicas Aplicadas, Pamplona, Spain – sequence: 25 givenname: Paul surname: Richardson fullname: Richardson, Paul organization: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and – sequence: 26 givenname: Pieter surname: Sonneveld fullname: Sonneveld, Pieter organization: Department of Hematology, Erasmus Medical Center and HOVON Data Center, Rotterdam, The Netherlands – sequence: 27 givenname: S Vincent surname: Rajkumar fullname: Rajkumar, S Vincent organization: Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25628469$$D View this record in MEDLINE/PubMed |
| BookMark | eNpN0E1LxDAQBuAgK-6H_gORHL1UM2napt5k0XVhxYvisaTprETbpCbp4t786RZcwdMM8z4zh5mTiXUWCTkHdgUg-XXdOtcknIFIgCc5ZCCLIzKDjMuEMc4m__opmYfwzkab8uyETHmWcynycka-V-iNit5oqkLAEDq0kfYeG6NjoGHwO7NTLVW2odF9GW2iwUCNpdg26Ns97fbYuk7RXo2JjeFmtHRtI3o7Tpwdlx8P5NX5D2Pf6Mq7oacee-fjKTneqjbg2aEuyMv93fPyIdk8rdbL202iM17GROS5AKmVKESDspYlK4stFtsSNGCaaclEjboBKAsBOpUaWCpq3XAQSpfbmi_I5e_d3rvPAUOsOhM0tq2y6IZQQZ4XqZBFLkd6caBD3WFT9d50yu-rv6_xH8BmdUs |
| CitedBy_id | crossref_primary_10_1177_2381468318814253 crossref_primary_10_1007_s12350_020_02281_3 crossref_primary_10_1111_bjh_16633 crossref_primary_10_1007_s11357_022_00698_x crossref_primary_10_1111_jgs_15710 crossref_primary_10_1007_s11912_019_0778_2 crossref_primary_10_1016_j_jgo_2018_09_003 crossref_primary_10_3390_cancers13184701 crossref_primary_10_1016_j_jgo_2020_07_011 crossref_primary_10_1038_s41375_018_0072_6 crossref_primary_10_1111_jgs_15835 crossref_primary_10_1200_EDBK_175171 crossref_primary_10_1111_jgs_15715 crossref_primary_10_1080_10428194_2019_1675881 crossref_primary_10_1002_cncr_33344 crossref_primary_10_1007_s00277_020_04356_0 crossref_primary_10_3390_jcm13010264 crossref_primary_10_1093_jncimonographs_lgac021 crossref_primary_10_1038_s41409_019_0478_4 crossref_primary_10_3390_jpm11040243 crossref_primary_10_1007_s00277_021_04529_5 crossref_primary_10_1016_j_jgo_2021_02_019 crossref_primary_10_4081_hr_2020_8956 crossref_primary_10_1111_ejh_13570 crossref_primary_10_1016_j_bbi_2024_04_019 crossref_primary_10_1016_j_jgo_2023_101680 crossref_primary_10_1016_j_jgo_2023_101681 crossref_primary_10_1200_JCO_2017_72_8170 crossref_primary_10_1016_j_jgo_2023_101684 crossref_primary_10_7748_ns_2025_e12403 crossref_primary_10_1182_blood_2018_09_874396 crossref_primary_10_1200_JCO_18_02096 crossref_primary_10_3390_life14030389 crossref_primary_10_1016_j_blre_2020_100670 crossref_primary_10_1038_s41598_021_02433_6 crossref_primary_10_1111_ejh_13009 crossref_primary_10_2147_CIA_S196087 crossref_primary_10_1007_s12254_018_0383_3 crossref_primary_10_1002_cncr_32357 crossref_primary_10_1177_107327481502204s02 crossref_primary_10_46989_001c_133682 crossref_primary_10_1002_cncr_30053 crossref_primary_10_3904_kjim_2015_408 crossref_primary_10_1002_jha2_40 crossref_primary_10_1016_j_maturitas_2020_04_015 crossref_primary_10_3390_hematolrep16040068 crossref_primary_10_1111_bjh_14304 crossref_primary_10_3390_cancers17050789 crossref_primary_10_1007_s11899_017_0368_z crossref_primary_10_2217_fon_2021_0778 crossref_primary_10_1016_j_clml_2024_09_006 crossref_primary_10_1016_j_jgo_2021_08_004 crossref_primary_10_1016_j_coph_2025_102527 crossref_primary_10_1038_s41408_023_00843_5 crossref_primary_10_14283_jfa_2019_25 crossref_primary_10_1586_17474086_2015_1078236 crossref_primary_10_1200_EDBK_280221 crossref_primary_10_1111_bjh_70041 crossref_primary_10_1016_j_jgo_2025_102199 crossref_primary_10_1182_blood_2017_05_736975 crossref_primary_10_1016_j_jgo_2025_102196 crossref_primary_10_1111_ejh_13357 crossref_primary_10_1007_s00277_023_05278_3 crossref_primary_10_1016_j_bbmt_2017_01_002 crossref_primary_10_1016_j_clml_2024_02_006 crossref_primary_10_1016_j_jgo_2018_10_010 crossref_primary_10_1097_CCO_0000000000001091 crossref_primary_10_1111_bjh_14549 crossref_primary_10_1159_000513737 crossref_primary_10_1182_blood_2015_02_626408 crossref_primary_10_1016_j_clml_2020_09_010 crossref_primary_10_1016_j_jgo_2018_03_015 crossref_primary_10_1111_bjh_14536 crossref_primary_10_1016_j_jgo_2020_06_002 crossref_primary_10_1002_cam4_620 crossref_primary_10_1002_ajh_25996 crossref_primary_10_1111_jdv_16607 crossref_primary_10_1002_hem3_85 crossref_primary_10_1080_17474086_2017_1326814 crossref_primary_10_1111_imj_16049 crossref_primary_10_1182_blood_2017_05_743203 crossref_primary_10_1016_j_jacadv_2025_101784 crossref_primary_10_1002_ajh_24891 crossref_primary_10_1080_10428194_2020_1786558 crossref_primary_10_1038_s41408_019_0176_x crossref_primary_10_21320_2500_2139_2025_18_3_218_226 crossref_primary_10_1111_bjh_16945 crossref_primary_10_1182_blood_2023020195 crossref_primary_10_1007_s11899_021_00646_0 crossref_primary_10_1182_blood_2017_09_746420 crossref_primary_10_3390_cancers15112910 crossref_primary_10_1080_17474086_2017_1285694 crossref_primary_10_1002_cam4_5228 crossref_primary_10_1016_j_critrevonc_2018_03_021 crossref_primary_10_3390_cancers16193329 crossref_primary_10_1002_ajh_24532 crossref_primary_10_1080_17474086_2018_1419861 crossref_primary_10_3109_10428194_2015_1131278 crossref_primary_10_1177_1078155219835303 crossref_primary_10_1111_imj_15182 crossref_primary_10_1080_14737140_2018_1496823 crossref_primary_10_1111_bjh_14514 crossref_primary_10_1080_14737140_2023_2213891 crossref_primary_10_1016_j_jgo_2021_02_009 crossref_primary_10_3389_fonc_2022_830922 crossref_primary_10_1016_j_critrevonc_2017_11_016 crossref_primary_10_1053_j_seminoncol_2019_09_001 crossref_primary_10_1182_blood_2021011144 crossref_primary_10_1002_cam4_5239 crossref_primary_10_1002_cam4_5234 crossref_primary_10_1016_j_clml_2016_06_001 crossref_primary_10_1016_j_jgo_2025_102266 crossref_primary_10_1016_j_clml_2020_03_017 crossref_primary_10_1007_s12185_020_02988_6 crossref_primary_10_1080_14656566_2018_1528229 crossref_primary_10_1016_j_ejim_2018_05_029 crossref_primary_10_3390_jpm13040666 crossref_primary_10_1185_03007995_2015_1105202 crossref_primary_10_1016_j_ejim_2018_05_027 crossref_primary_10_1182_blood_2019001300 crossref_primary_10_1007_s40266_015_0265_x crossref_primary_10_1038_s41571_025_01041_x crossref_primary_10_1200_EDBK_238527 crossref_primary_10_1038_s41408_025_01297_7 crossref_primary_10_1002_cam4_5245 crossref_primary_10_1111_ejh_13439 crossref_primary_10_1080_10428194_2025_2513676 crossref_primary_10_3390_cancers17152579 crossref_primary_10_1016_j_clml_2021_11_003 crossref_primary_10_1111_bjh_15700 crossref_primary_10_1007_s12185_024_03904_y crossref_primary_10_1053_j_seminoncol_2020_02_010 crossref_primary_10_1371_journal_pone_0270854 crossref_primary_10_1080_10428194_2024_2443550 crossref_primary_10_1158_1078_0432_CCR_16_0861 crossref_primary_10_1002_onco_13610 crossref_primary_10_1038_s41409_019_0631_0 crossref_primary_10_1182_blood_2020008787 crossref_primary_10_1002_jha2_743 crossref_primary_10_1002_ajh_25797 crossref_primary_10_3390_ph14010020 crossref_primary_10_1002_ajh_25310 crossref_primary_10_1016_j_jgo_2017_02_007 crossref_primary_10_1200_EDBK_432220 crossref_primary_10_3390_cancers11010048 crossref_primary_10_1007_s11912_024_01545_2 crossref_primary_10_3390_cancers15092633 crossref_primary_10_1016_j_jgo_2017_02_004 crossref_primary_10_1080_17474086_2021_1983426 crossref_primary_10_1016_S2352_3026_25_00143_7 crossref_primary_10_1111_ejh_14152 crossref_primary_10_1002_cncr_33170 crossref_primary_10_1080_17474086_2020_1739517 crossref_primary_10_1016_S2352_3026_16_30049_7 crossref_primary_10_1038_leu_2016_36 crossref_primary_10_1016_S2665_9913_24_00230_3 crossref_primary_10_1007_s12288_016_0647_1 crossref_primary_10_1016_j_jgo_2022_10_016 crossref_primary_10_1016_S0140_6736_21_00135_5 crossref_primary_10_1182_blood_2017_05_693606 crossref_primary_10_1002_ajh_26512 crossref_primary_10_1002_ajh_26753 crossref_primary_10_1002_cam4_5422 crossref_primary_10_1007_s11136_019_02304_8 crossref_primary_10_1007_s11899_018_0454_x crossref_primary_10_1016_j_clml_2019_04_014 crossref_primary_10_1016_j_jgo_2024_102077 crossref_primary_10_1016_S2352_3026_18_30220_5 crossref_primary_10_1200_JCO_2016_69_2517 crossref_primary_10_1016_j_clml_2024_11_005 crossref_primary_10_2147_OTT_S300834 crossref_primary_10_1111_bjh_15800 crossref_primary_10_1188_21_ONF_291_307 crossref_primary_10_1016_j_jgo_2020_09_031 crossref_primary_10_1007_s00277_019_03794_9 crossref_primary_10_1080_14656566_2018_1515914 crossref_primary_10_1007_s40266_018_0539_1 crossref_primary_10_1007_s00277_019_03816_6 crossref_primary_10_1080_14779072_2017_1409114 crossref_primary_10_1007_s00277_019_03640_y crossref_primary_10_1016_j_jgo_2022_01_007 crossref_primary_10_1200_JCO_2016_68_6113 crossref_primary_10_1016_j_jtct_2023_05_001 crossref_primary_10_1038_s41408_022_00782_7 crossref_primary_10_1007_s12185_021_03262_z crossref_primary_10_1182_blood_2024025939 crossref_primary_10_1182_bloodadvances_2020001965 crossref_primary_10_1080_17474086_2021_1886073 crossref_primary_10_1007_s00520_022_06920_y crossref_primary_10_1186_s12957_025_03982_0 crossref_primary_10_3390_biomedicines11072087 crossref_primary_10_1002_ajh_24796 crossref_primary_10_1002_ajh_25764 crossref_primary_10_1038_s41408_021_00464_w crossref_primary_10_1016_j_jgo_2024_102051 crossref_primary_10_1007_s11912_024_01558_x crossref_primary_10_1016_j_clml_2021_06_005 crossref_primary_10_3390_cancers15071929 crossref_primary_10_1080_17474086_2020_1729734 crossref_primary_10_2217_fon_2023_0604 crossref_primary_10_1016_j_clml_2019_09_610 crossref_primary_10_1080_17474086_2019_1634541 crossref_primary_10_1038_bmt_2017_192 crossref_primary_10_3390_cancers10070225 crossref_primary_10_3389_fonc_2024_1373548 crossref_primary_10_1038_s41408_018_0141_0 crossref_primary_10_1038_s41409_018_0379_y crossref_primary_10_1002_ajh_24389 crossref_primary_10_1007_s00277_018_3449_8 crossref_primary_10_1111_bjh_18295 crossref_primary_10_1038_s41375_023_02105_6 crossref_primary_10_1038_s41408_021_00432_4 crossref_primary_10_1177_10781552231190009 crossref_primary_10_1016_j_jgo_2025_102321 crossref_primary_10_1038_bmt_2017_23 crossref_primary_10_1002_ijc_33762 crossref_primary_10_1007_s00277_016_2743_6 crossref_primary_10_1038_s41409_020_01026_7 crossref_primary_10_1182_blood_2017_03_726703 crossref_primary_10_1016_j_jgo_2025_102329 crossref_primary_10_1111_bjh_13608 crossref_primary_10_1007_s11136_023_03390_5 crossref_primary_10_3389_fphar_2020_561601 crossref_primary_10_3390_cancers14010258 crossref_primary_10_1007_s10238_023_01002_7 crossref_primary_10_1186_s13063_022_06848_y crossref_primary_10_1007_s00277_024_06006_1 crossref_primary_10_12968_hmed_2017_78_2_C21 crossref_primary_10_1016_j_clml_2023_01_016 crossref_primary_10_3390_cancers16091689 crossref_primary_10_1111_ejh_13496 crossref_primary_10_1038_s41416_019_0581_8 crossref_primary_10_1111_imj_70148 crossref_primary_10_3390_hemato5020010 crossref_primary_10_1002_ajh_26319 crossref_primary_10_1007_s00277_021_04592_y crossref_primary_10_3389_fonc_2020_00676 crossref_primary_10_1007_s12672_024_01305_5 crossref_primary_10_3390_cancers13174320 crossref_primary_10_1016_j_clml_2020_06_023 crossref_primary_10_1016_j_blre_2019_100616 crossref_primary_10_1038_s41409_020_01159_9 crossref_primary_10_3390_cancers16091774 crossref_primary_10_1007_s00277_018_3546_8 crossref_primary_10_1007_s11899_019_00500_4 crossref_primary_10_1080_17474086_2018_1537776 crossref_primary_10_1007_s00520_018_4502_9 crossref_primary_10_1016_j_leukres_2023_107393 crossref_primary_10_1080_16078454_2025_2496545 crossref_primary_10_1016_j_jgo_2018_05_015 crossref_primary_10_1016_j_clml_2020_12_021 crossref_primary_10_1053_j_seminoncol_2021_11_003 crossref_primary_10_1136_bmjspcare_2018_001516 crossref_primary_10_1002_ajh_24236 crossref_primary_10_1002_ajh_24478 crossref_primary_10_1080_17474086_2021_1905513 crossref_primary_10_1007_s11912_019_0804_4 crossref_primary_10_1097_HS9_0000000000000163 crossref_primary_10_1038_bmt_2016_174 crossref_primary_10_1186_s13045_024_01569_y crossref_primary_10_1080_17843286_2020_1860411 crossref_primary_10_3390_cancers12102885 crossref_primary_10_1038_s41408_023_00795_w crossref_primary_10_1182_blood_2019001299 crossref_primary_10_3390_life13122259 crossref_primary_10_3389_fonc_2023_1103687 crossref_primary_10_1007_s00277_020_04240_x crossref_primary_10_1080_10428194_2017_1365859 crossref_primary_10_3389_fonc_2021_775050 crossref_primary_10_1016_S2352_3026_25_00162_0 crossref_primary_10_1111_bjh_16194 crossref_primary_10_1200_JCO_2016_66_7295 crossref_primary_10_1016_j_clml_2016_04_010 crossref_primary_10_1016_j_ejca_2024_114153 crossref_primary_10_1097_CCO_0000000000000213 crossref_primary_10_3390_medicina60111905 crossref_primary_10_1097_HS9_0000000000000726 crossref_primary_10_1002_jcla_24375 crossref_primary_10_3390_cancers17060944 crossref_primary_10_1080_17474086_2016_1196127 crossref_primary_10_1016_j_clml_2021_07_013 crossref_primary_10_1371_journal_pone_0262388 crossref_primary_10_1038_s41409_024_02227_0 crossref_primary_10_1200_EDBK_25_473316 crossref_primary_10_3389_fmed_2021_712070 crossref_primary_10_1016_j_jtct_2023_03_012 crossref_primary_10_1016_j_banm_2022_07_006 crossref_primary_10_1007_s11899_016_0348_8 crossref_primary_10_1016_j_jgo_2019_07_004 crossref_primary_10_1007_s00277_018_3568_2 crossref_primary_10_1002_ajh_27206 crossref_primary_10_1002_ajh_27327 crossref_primary_10_1016_j_critrevonc_2018_07_003 crossref_primary_10_1016_S2352_3026_21_00241_6 crossref_primary_10_1016_j_clml_2023_03_007 crossref_primary_10_1016_S2352_3026_19_30011_0 crossref_primary_10_1080_10428194_2020_1749608 crossref_primary_10_3390_cancers15245709 crossref_primary_10_1016_j_critrevonc_2019_02_011 crossref_primary_10_1007_s12325_021_01824_5 crossref_primary_10_1016_j_jgo_2020_04_015 crossref_primary_10_3389_fmed_2021_612696 crossref_primary_10_1007_s12185_022_03360_6 crossref_primary_10_1038_s41375_020_0918_6 crossref_primary_10_1111_bjh_17148 crossref_primary_10_1016_j_jgo_2020_04_010 crossref_primary_10_1038_s41375_021_01453_5 crossref_primary_10_1111_imj_14886 crossref_primary_10_1097_PPO_0000000000000529 crossref_primary_10_1080_14656566_2019_1577822 crossref_primary_10_1038_s41375_019_0595_5 crossref_primary_10_1182_bloodadvances_2025015973 crossref_primary_10_1097_CCO_0000000000000792 crossref_primary_10_1093_annonc_mdx096 crossref_primary_10_3390_cancers14194741 crossref_primary_10_1007_s00277_024_06143_7 crossref_primary_10_1038_s41375_021_01488_8 crossref_primary_10_1002_cam4_1128 crossref_primary_10_1080_10428194_2024_2419375 crossref_primary_10_3390_cancers12123497 crossref_primary_10_1080_10428194_2019_1636989 crossref_primary_10_1182_blood_2020008733 crossref_primary_10_1002_cam4_2698 crossref_primary_10_1200_EDBK_320105 crossref_primary_10_1016_j_jgo_2020_04_008 crossref_primary_10_1111_bjh_16282 crossref_primary_10_1016_S2152_2650_21_02359_4 crossref_primary_10_1016_j_lpm_2024_104266 crossref_primary_10_3389_fcvm_2021_681484 crossref_primary_10_1016_j_mayocp_2017_01_003 crossref_primary_10_1038_s41375_018_0142_9 crossref_primary_10_1016_S0001_4079_19_30260_2 crossref_primary_10_1016_j_hoc_2023_12_007 crossref_primary_10_1016_j_clon_2023_11_003 crossref_primary_10_1016_j_hoc_2023_12_002 crossref_primary_10_1182_blood_2015_08_662627 crossref_primary_10_1007_s00277_022_04857_0 crossref_primary_10_1016_j_clml_2025_06_005 crossref_primary_10_1007_s00277_020_04162_8 crossref_primary_10_1016_j_clml_2018_01_005 crossref_primary_10_1111_bjh_18336 crossref_primary_10_1111_den_13592 crossref_primary_10_1016_j_jgo_2022_08_018 crossref_primary_10_1517_14656566_2015_1075507 crossref_primary_10_1634_theoncologist_2018_0890 crossref_primary_10_1007_s11899_016_0323_4 crossref_primary_10_1038_bmt_2015_185 crossref_primary_10_1016_S2152_2650_20_30470_5 crossref_primary_10_1016_j_jgo_2020_12_001 crossref_primary_10_1038_s41408_023_00849_z crossref_primary_10_1080_10428194_2018_1427858 crossref_primary_10_1007_s40265_017_0841_y crossref_primary_10_1007_s12185_016_2099_7 crossref_primary_10_1016_j_soncn_2017_05_003 crossref_primary_10_1016_j_soncn_2017_05_004 crossref_primary_10_1016_j_soncn_2017_05_009 crossref_primary_10_1002_aac2_12022 crossref_primary_10_1016_j_bbmt_2019_01_028 crossref_primary_10_1038_s41375_021_01247_9 crossref_primary_10_1016_j_bbmt_2017_06_001 crossref_primary_10_1188_17_CJON_240_249 crossref_primary_10_1016_j_clml_2023_10_009 crossref_primary_10_1182_blood_2024025868 crossref_primary_10_1002_ajh_27473 crossref_primary_10_1111_bjh_19648 crossref_primary_10_1080_10428194_2021_1950708 crossref_primary_10_3390_cancers13123053 crossref_primary_10_1007_s42058_020_00038_y crossref_primary_10_12998_wjcc_v11_i24_5643 crossref_primary_10_1016_j_cger_2015_08_012 crossref_primary_10_1111_bjh_18672 crossref_primary_10_1182_blood_2015_05_612960 crossref_primary_10_3390_cancers15102693 crossref_primary_10_1080_14737159_2019_1583103 crossref_primary_10_1038_s41409_021_01308_8 crossref_primary_10_1080_01621424_2021_2023063 crossref_primary_10_1016_j_ccc_2020_08_007 crossref_primary_10_1080_14796694_2025_2504318 crossref_primary_10_1200_EDBK_200841 crossref_primary_10_1200_EDBK_239067 crossref_primary_10_3390_biomedicines13010145 crossref_primary_10_1016_j_jgo_2016_08_001 crossref_primary_10_1182_bloodadvances_2024012727 crossref_primary_10_1016_j_bbmt_2016_11_007 crossref_primary_10_1186_s12955_018_0953_4 crossref_primary_10_1016_j_jgo_2019_09_012 crossref_primary_10_1080_17474086_2020_1804356 crossref_primary_10_1111_bjh_15273 crossref_primary_10_3389_fonc_2022_922039 crossref_primary_10_1182_blood_2020009507 crossref_primary_10_1093_jjco_hyac111 crossref_primary_10_1159_000541541 crossref_primary_10_1038_leu_2015_209 crossref_primary_10_3390_hematolrep15010015 crossref_primary_10_1080_17474086_2017_1317589 crossref_primary_10_1016_j_lpm_2019_07_023 crossref_primary_10_1111_bjh_15260 crossref_primary_10_1111_jcpt_12606 crossref_primary_10_1016_j_mayocp_2015_11_007 crossref_primary_10_1002_cnr2_1476 crossref_primary_10_1016_j_jgo_2020_05_004 crossref_primary_10_12968_bjon_2016_25_S18 crossref_primary_10_1016_j_clml_2016_02_015 crossref_primary_10_1111_ejh_13861 crossref_primary_10_1080_17474086_2017_1350166 crossref_primary_10_1038_s41375_020_0976_9 crossref_primary_10_2217_fon_2020_1280 crossref_primary_10_1038_s41375_019_0539_0 crossref_primary_10_1111_bjh_19978 crossref_primary_10_1016_j_clml_2025_09_007 crossref_primary_10_1111_bjh_16469 crossref_primary_10_1111_bjh_16105 crossref_primary_10_12688_f1000research_8777_1 crossref_primary_10_1080_17474086_2019_1645005 crossref_primary_10_1016_j_jgo_2020_05_013 crossref_primary_10_1136_bmjopen_2021_056147 crossref_primary_10_1007_s15015_015_2159_5 crossref_primary_10_1007_s00277_018_3258_0 crossref_primary_10_1111_ejh_12882 crossref_primary_10_1016_j_jgo_2016_04_001 crossref_primary_10_3390_cancers12113488 crossref_primary_10_1080_17474086_2016_1204908 crossref_primary_10_1002_ajh_26080 crossref_primary_10_1371_journal_pone_0208920 crossref_primary_10_1038_s41572_024_00529_7 crossref_primary_10_1038_s41408_022_00779_2 crossref_primary_10_3390_jcm9113554 crossref_primary_10_1007_s11899_019_00507_x crossref_primary_10_1016_j_jgo_2020_10_009 crossref_primary_10_1016_j_jgo_2016_07_010 crossref_primary_10_1111_bjh_14033 crossref_primary_10_1111_ejh_13760 crossref_primary_10_1038_bcj_2015_91 crossref_primary_10_1002_acg2_95 crossref_primary_10_1097_CCO_0000000000000395 crossref_primary_10_1007_s00520_018_4410_z crossref_primary_10_1016_j_ctrv_2016_10_004 crossref_primary_10_1038_s41408_021_00414_6 crossref_primary_10_1038_s41375_018_0098_9 crossref_primary_10_1007_s11912_021_01097_9 crossref_primary_10_1007_s12288_025_02069_w crossref_primary_10_1016_j_jgo_2021_12_004 crossref_primary_10_1002_hon_2379 crossref_primary_10_1002_ajh_26172 crossref_primary_10_1182_bloodadvances_2023012539 crossref_primary_10_1016_j_lrr_2015_09_002 crossref_primary_10_1111_bjh_17410 crossref_primary_10_1007_s00391_020_01701_w crossref_primary_10_1200_JCO_2018_78_8687 crossref_primary_10_1080_13543784_2017_1324571 crossref_primary_10_3390_cancers12113106 crossref_primary_10_1186_s12885_020_6637_6 crossref_primary_10_1053_j_seminoncol_2022_01_002 crossref_primary_10_1007_s00432_019_03101_z crossref_primary_10_1111_ejh_13707 crossref_primary_10_1002_hon_2422 crossref_primary_10_1016_j_clml_2016_11_010 crossref_primary_10_1200_EDBK_158639 crossref_primary_10_1182_bloodadvances_2023011019 crossref_primary_10_1182_bloodadvances_2024014970 crossref_primary_10_1182_bloodadvances_2021004777 crossref_primary_10_3390_cancers17030525 crossref_primary_10_1080_14656566_2017_1340942 crossref_primary_10_3390_cancers15133469 crossref_primary_10_1080_17474086_2018_1437345 crossref_primary_10_1007_s12288_017_0777_0 crossref_primary_10_3389_fonc_2023_1110693 crossref_primary_10_1016_j_jgo_2024_101735 crossref_primary_10_1159_000477792 crossref_primary_10_1007_s00277_017_2991_0 crossref_primary_10_1038_s41375_020_0713_4 crossref_primary_10_1182_blood_2022017635 crossref_primary_10_3390_bioengineering11080846 crossref_primary_10_1038_s41409_020_0979_1 crossref_primary_10_1002_cncr_33658 crossref_primary_10_1007_s00256_021_03841_5 crossref_primary_10_1007_s00277_019_03844_2 crossref_primary_10_1007_s10238_025_01683_2 crossref_primary_10_3390_cancers15051558 crossref_primary_10_3390_cancers17172904 crossref_primary_10_1093_nop_npz040 crossref_primary_10_1038_s41591_024_03485_7 crossref_primary_10_1177_2040620718761776 crossref_primary_10_1016_j_jgo_2016_06_003 crossref_primary_10_1200_EDBK_390202 crossref_primary_10_1007_s11912_025_01639_5 crossref_primary_10_1038_s41375_021_01162_z crossref_primary_10_1080_10428194_2024_2340052 crossref_primary_10_1080_10428194_2018_1509323 crossref_primary_10_1080_17474086_2019_1555460 crossref_primary_10_1177_2040620716680548 crossref_primary_10_1016_j_jgo_2024_101734 crossref_primary_10_3390_cancers11122015 crossref_primary_10_1016_j_jgo_2023_101538 crossref_primary_10_3389_fonc_2022_1096852 crossref_primary_10_1016_j_jgo_2016_12_008 crossref_primary_10_1016_j_jgo_2023_101536 crossref_primary_10_3390_cancers12123576 crossref_primary_10_1188_17_CJON_S5_47_59 crossref_primary_10_1016_j_jgo_2019_02_002 crossref_primary_10_1007_s00761_024_01659_z crossref_primary_10_1182_bloodadvances_2024014624 crossref_primary_10_1186_s12916_025_04086_y crossref_primary_10_1038_s41375_020_0712_5 crossref_primary_10_1093_jjco_hyac198 crossref_primary_10_1080_10428194_2025_2482134 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1182/blood-2014-12-615187 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| ExternalDocumentID | 25628469 |
| Genre | Journal Article |
| GroupedDBID | --- -~X .55 0R~ 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6J9 AAEDW AAXUO ABOCM ACGFO ADBBV ADVLN AENEX AFOSN AGCQF AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD EX3 F5P FDB FRP GS5 GX1 H13 IH2 K-O KQ8 L7B LSO MJL N9A NPM OK1 P2P R.V RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV 7X8 AALRI ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP EFKBS |
| ID | FETCH-LOGICAL-c529t-466418ca474de8b89097fe7f91c1e35c804becd119741c38c1034bcd214ac9fb2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 610 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000354626300012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1528-0020 |
| IngestDate | Sun Sep 28 11:00:34 EDT 2025 Sun May 11 04:07:31 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 13 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c529t-466418ca474de8b89097fe7f91c1e35c804becd119741c38c1034bcd214ac9fb2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://dx.doi.org/10.1182/blood-2014-12-615187 |
| PMID | 25628469 |
| PQID | 1667348768 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1667348768 pubmed_primary_25628469 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-Mar-26 20150326 |
| PublicationDateYYYYMMDD | 2015-03-26 |
| PublicationDate_xml | – month: 03 year: 2015 text: 2015-Mar-26 day: 26 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2015 |
| References | 25814486 - Blood. 2015 Mar 26;125(13):2014-5. doi: 10.1182/blood-2015-02-626408 29732537 - Br J Haematol. 2018 Jul;182(2):165-167. doi: 10.1111/bjh.15260 31265505 - Blood. 2016 Aug 18;128(7):1020. doi: 10.1182/blood-2016-07-727081 31265500 - Blood. 2016 Mar 3;127(9):1213. doi: 10.1182/blood-2016-01-693390 Blood. 2016 Mar 3;127(9):1213 |
| References_xml | – reference: 29732537 - Br J Haematol. 2018 Jul;182(2):165-167. doi: 10.1111/bjh.15260 – reference: - Blood. 2016 Mar 3;127(9):1213 – reference: 25814486 - Blood. 2015 Mar 26;125(13):2014-5. doi: 10.1182/blood-2015-02-626408 – reference: 31265505 - Blood. 2016 Aug 18;128(7):1020. doi: 10.1182/blood-2016-07-727081 – reference: 31265500 - Blood. 2016 Mar 3;127(9):1213. doi: 10.1182/blood-2016-01-693390 |
| SSID | ssj0014325 |
| Score | 2.6473672 |
| Snippet | We conducted a pooled analysis of 869 individual newly diagnosed elderly patient data from 3 prospective trials. At diagnosis, a geriatric assessment had been... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2068 |
| SubjectTerms | Aged Aged, 80 and over Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Clinical Trials as Topic Cohort Studies Frail Elderly Geriatric Assessment Humans Multiple Myeloma - drug therapy Multiple Myeloma - mortality Prognosis Withholding Treatment - statistics & numerical data |
| Title | Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/25628469 https://www.proquest.com/docview/1667348768 |
| Volume | 125 |
| WOSCitedRecordID | wos000354626300012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB5868VHfb8YQbyFJs2m2fUiVXwcbOlBobey2WygYJNqqtibP93ZzVbxIAheQg47ELJfZr6dmXwDcEqcPMpYknlZJuiAEujE40oo-vCiKKVwRv7Q6szex50O7_VE1yXcStdWOfWJ1lGnhTI58npg5lMSu27yi9GzZ6ZGmeqqG6ExC_MhURmD6rj3XUVgoR26SiGKe4YXuV_niFLXq7Zwin5Wtc-EdR7_TjJtsLlZ--9jrsOqo5nYqnCxATM6r8FmK6cj9nCCZ2gbP21GvQaLl9O75avp-LcaLLVd1X0TPm4NTI2UP8ovIU8cvZgF4xLLV3I3BFiUeYrj4p2sjEorDnLUZgb40wSHE_1UDCU6FdfynNbij2Qktt0Sl71HmxTDqqSxBY831w9Xd56b3OCpqCHGntGsD7iSLGap5gkXvogzHRMcVKDDSHGfEXZSU8JkgQq5CvyQJSptBEwqkSWNbZjLi1zvAuqMq4jpyJeJzxQn00RKRW6kSd5JKL0HJ9ON6NMbMuUOmevitex_b8Ue7FS72R9VEh59InoUl5ti_w_WB7BCOIlM41mjeQjzGfkFfQQL6m08KF-OLeTo2um2PwGbDOMT |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Geriatric+assessment+predicts+survival+and+toxicities+in+elderly+myeloma+patients%3A+an+International+Myeloma+Working+Group+report&rft.jtitle=Blood&rft.au=Palumbo%2C+Antonio&rft.au=Bringhen%2C+Sara&rft.au=Mateos%2C+Maria-Victoria&rft.au=Larocca%2C+Alessandra&rft.date=2015-03-26&rft.issn=1528-0020&rft.eissn=1528-0020&rft.volume=125&rft.issue=13&rft.spage=2068&rft_id=info:doi/10.1182%2Fblood-2014-12-615187&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-0020&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-0020&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-0020&client=summon |